This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Raltitrexed

Authoring team

Raltitrexed is an inhibitor of thymidylate synthase. It is licensed for use as monotherapy when fluorouracil-based palliative therapy for colorectal cancer is inappropriate or not tolerated (1).

Adverse effects:

  • raltitrexed is more likely than infused fluorouracil/folinic acid to cause severe nausea, diarrhoea, anorexia, lethargy, neutropenia and thrombocytopenia (1)
  • if raltitrexed is used then monitoring of renal function is essential (dose should be adjusted if creatinine clearance is below 65 mL/minute) (1)

Reference:

  1. Drug and Therapeutics Bulletin (2002), 40(7), 50-2.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.